Appian and PSI CRO Launch Strategic Partnership for AI-Driven Clinical Trial Operations

Appian and PSI CRO announced a strategic partnership on October 28, 2026, launching their first joint AI-powered process orchestration solution designed to automate clinical trial site identification and selection across therapeutic areas and geographies. According to the announcement, the live solution integrates manual, decentralized steps into a single digital process to improve efficiency and transparency.

Solution Capabilities and Integration

• Process Orchestration: Connects people, data, systems, and AI in a single workflow to manage routing and exceptions.
• System Integration: Integrates with PSI's core systems and data warehouse, alongside Appian's AI and process intelligence capabilities.
• Gartner Recognition: The Appian Platform relies on capabilities recognized by Gartner as a Leader in the 2026 Magic Quadrant for Business Orchestration and Automation Technologies (BOAT).

Future Outlook and Strategic Goals

Kirill Soldatov, Head of Process Improvement at PSI, stated that the solution aims to create a scalable foundation for more predictable, accurate, and timely site selection worldwide, targeting the reduction or elimination of non-enrolling sites and patient enrollment delays. Alexander Motie, Regional Vice President DACH & Eastern Europe at Appian, noted that the project demonstrates the value of embedding AI into business processes. Following this initial deployment, both companies plan to evaluate further use cases to extend AI-powered orchestration across the clinical trial lifecycle.

Practical Implications and Verification

Life sciences organizations and industry observers can review the original press release on PR Newswire or visit the official corporate websites of Appian and PSI CRO for further details regarding product announcements and forward-looking statements. Readers should independently verify technical specifications and deployment timelines directly with the companies.